Free Trial

Progyny (NASDAQ:PGNY) Trading 7% Higher - Time to Buy?

Progyny logo with Medical background

Key Points

  • Progyny shares increased by 7%, reaching a last trade price of $21.74, although the trading volume was down 57% from average levels.
  • Analysts have mixed opinions on Progyny, with a majority offering a "Moderate Buy" rating and a price target average of $25.44, while one analyst recommended a "Strong Buy" with a target of $28.00.
  • Progyny's recent quarterly results showed earnings per share of $0.19, missing estimates, but revenue increased by 9.5% year-over-year, totaling $332.87 million.
  • Five stocks we like better than Progyny.

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) shares traded up 7% on Thursday . The company traded as high as $20.94 and last traded at $21.74. 580,255 shares traded hands during trading, a decline of 57% from the average session volume of 1,358,235 shares. The stock had previously closed at $20.32.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PGNY shares. Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective for the company in a research report on Tuesday, July 8th. Leerink Partnrs raised shares of Progyny from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 8th. Weiss Ratings reissued a "hold (c-)" rating on shares of Progyny in a research report on Wednesday, October 8th. Raymond James Financial set a $28.00 price objective on shares of Progyny in a research report on Friday, August 8th. Finally, Truist Financial boosted their price objective on shares of Progyny from $24.00 to $27.00 and gave the company a "hold" rating in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $25.44.

Check Out Our Latest Analysis on PGNY

Progyny Price Performance

The company has a 50-day moving average price of $22.13 and a 200 day moving average price of $22.17. The firm has a market capitalization of $1.83 billion, a PE ratio of 36.09, a P/E/G ratio of 1.72 and a beta of 1.34.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The company had revenue of $332.87 million for the quarter, compared to the consensus estimate of $315.70 million. During the same period last year, the company earned $0.17 EPS. The firm's revenue for the quarter was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, research analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Activity

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the transaction, the director owned 12,501 shares of the company's stock, valued at $275,522.04. This represents a 16.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the transaction, the executive vice president directly owned 79,697 shares of the company's stock, valued at $1,829,843.12. This trade represents a 2.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,895 shares of company stock valued at $179,311 in the last three months. Insiders own 9.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its holdings in shares of Progyny by 0.7% in the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company's stock valued at $1,549,000 after acquiring an additional 457 shares during the last quarter. New York State Teachers Retirement System lifted its stake in Progyny by 0.7% in the first quarter. New York State Teachers Retirement System now owns 73,200 shares of the company's stock worth $1,635,000 after purchasing an additional 500 shares during the last quarter. Leibman Financial Services Inc. lifted its stake in Progyny by 1.1% in the second quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company's stock worth $1,011,000 after purchasing an additional 513 shares during the last quarter. Teza Capital Management LLC lifted its stake in Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company's stock worth $221,000 after purchasing an additional 516 shares during the last quarter. Finally, Oxford Asset Management LLP lifted its stake in Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company's stock worth $284,000 after purchasing an additional 531 shares during the last quarter. Institutional investors own 94.93% of the company's stock.

Progyny Company Profile

(Get Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Progyny Right Now?

Before you consider Progyny, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.

While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.